GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Bio-heart Biological Technology Co Ltd (HKSE:02185) » Definitions » Tax Expense

Shanghai Bio-heart Biological Technology Co (HKSE:02185) Tax Expense : HK$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Bio-heart Biological Technology Co Tax Expense?

Shanghai Bio-heart Biological Technology Co's tax expense for the months ended in Jun. 2024 was HK$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.00 Mil.


Shanghai Bio-heart Biological Technology Co Tax Expense Historical Data

The historical data trend for Shanghai Bio-heart Biological Technology Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Bio-heart Biological Technology Co Tax Expense Chart

Shanghai Bio-heart Biological Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
- - - - -

Shanghai Bio-heart Biological Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Shanghai Bio-heart Biological Technology Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Bio-heart Biological Technology Co  (HKSE:02185) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Shanghai Bio-heart Biological Technology Co Tax Expense Related Terms

Thank you for viewing the detailed overview of Shanghai Bio-heart Biological Technology Co's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Bio-heart Biological Technology Co Business Description

Traded in Other Exchanges
N/A
Address
No.590 Ruiqing Road, Room 302, 3rd Floor, Building 4 & Building 6, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Shanghai Bio-heart Biological Technology Co Ltd is engaged in the research and development of bioresorbable scaffold (BRS) products and the renal denervation (RDN) system. The company is a interventional cardiovascular device company in China, and locate in Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. Focused on two therapies, bioresorbable scaffolds (BRS) and renal denervation (RDN), addressing the unmet medical needs of Chinese patients for the treatment of coronary and peripheral artery diseases and uncontrolled hypertension.
Executives
Tpg Operating Group Ii, L.p. 2201 Interest of corporation controlled by you
Chen Hao 2201 Interest of corporation controlled by you
Zhu Linan 2201 Interest of corporation controlled by you
Wang Nengguang 2201 Interest of corporation controlled by you
Union Season Holdings Limited 2201 Interest of corporation controlled by you
Sk China Company Limited 2201 Interest of corporation controlled by you
Right Lane Limited 2201 Interest of corporation controlled by you
Proud Solar Limited 2201 Interest of corporation controlled by you
Magic Grace Limited 2101 Beneficial owner
Loft Success Investments Limited 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii, L.p. 2201 Interest of corporation controlled by you
Lc Healthcare Fund Ii Gp Limited 2201 Interest of corporation controlled by you
Lc Fund Gp Limited 2201 Interest of corporation controlled by you
Great Unity Fund I, L.p. 2201 Interest of corporation controlled by you
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Bio-heart Biological Technology Co Headlines

No Headlines